The Methodist Hospital System
The Methodist Hospital System. Leading Medicine

Clinical Trials

Clinical Trials at The Methodist Hospital Research Institute

Search results...

Cancers and Other Neoplasms
Active and enrolling clinical trials for Cancers and Other Neoplasms are updated on this page as they become available. You are also welcome to view our clinical trials that are registered with the National Institutes of Health.
 
For more information please contact the study coordinator of the trials listed below or contact the main clinical trials help line 713-441-3250.
 
Brain and Central Nervous System Cancers

NovoCure EF-14
Study Status: Active/Enrolling
Investigator: New, Pamela
Study Coordinator: Harris, Kimbra
Phone: 713-441-3834
Summary:The study is a prospective, randomly controlled pivotal trial, designed to test the efficacy and safety of a medical device, the NovoTTF-100A, as an adjuvant to the best standard of care in the treatm...(read more)

RTOG 0913
Study Status: Active/Enrolling
Investigator: New, Pamela
Study Coordinator: Harris, Kimbra
Phone: 713-441-3834
Summary:RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as temozolomid...(read more)

RTOG 0929
Study Status: Active/Enrolling
Investigator: New, Pamela
Study Coordinator: Harris, Kimbra
Phone: 713-441-3834
Summary:RATIONALE: ABT-888 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide. work in different ways to stop the growt...(read more)
Brain Cancers

NovoCure EF-14
Study Status: Active/Enrolling
Investigator: New, Pamela
Study Coordinator: Harris, Kimbra
Phone: 713-441-3834
Summary:The study is a prospective, randomly controlled pivotal trial, designed to test the efficacy and safety of a medical device, the NovoTTF-100A, as an adjuvant to the best standard of care in the treatm...(read more)
Breast Cancers

BP22572 T-DM1 in Breast Cancer
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Froehlich, Amber
Phone: 713-441-0685
Summary:This open-label, multi-center study will assess the safety and tolerability of adding trastuzumab emtansine (T-DM1) to docetaxel in patients with locally advanced or metastatic HER2-positive breast ca...(read more)

CAT Trial
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Salazar, Maria
Phone: 713-441-6011
Summary:The major purpose of this research study is to better understand how therapy works on different patients. This study is being offered to patients with a diagnosis of advanced or metastatic breast canc...(read more)

Denosumab - Breast Cancer
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Boone, Toniva
Phone: 7134410686
Summary:Purpose: This randomized phase 3 trial is studying the effect of denosumab to see if it can prevent disease recurrence in the bone or in any other part of the body, when it is given as adjuvant therap...(read more)

ECOG 2108
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Salazar, Maria
Phone: 713-441-6011
Summary:RATIONALE: Early surgery may have fewer side effects and improve recovery. Palliative surgery or radiation therapy may help patients with advanced breast cancer live more comfortably. It is not yet kn...(read more)

Ganetespib STA-9090 for Metastatic HER2 Positive or Triple Negative Breast Cancer
Study Status: Active/Enrolling
Investigator: Rodriguez, Angel
Study Coordinator: Salazar, Maria
Phone: 713-441-6011
Summary:The purpose of this study is to determine if ganetespib (STA-9090) is effective in the treatment of patients with HER2+ or triple negative breast cancer who have not received prior systemic treatment ...(read more)

ICE Trial
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Salazar, Maria
Phone: 713-441-6011
Summary:Ixabepilone and capecitabine combination has demonstrated to be an active regimen in patients with metastatic breast cancer (MBC) after failing an anthracycline and a taxane regimen. Cetuximab is acti...(read more)

M12-895 Abbott Phase II
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Salazar, Maria
Phone: 713-441-6011
Summary:The Study Evaluating Efficacy And Tolerability of Veliparib in Combination with Temozolomide or Veliparib/Placebo in Combination with Carboplatin and Paclitaxel in Subjects with Breast Cancer Gene (BR...(read more)

MEDI573 in Metastatic Breast Cancer
Study Status: Active/Enrolling
Investigator: Rodriguez, Angel
Study Coordinator: Salazar, Maria
Phone: 713-441-6011
Summary:This is a Phase 1b/2, multicenter, open-label study to evaluate the safety, tolerability, antitumor activity, and pharmacology of MEDI-573 in combination with an AI in adult subjects with HR+, HER2-ne...(read more)

Neoadjuvant Gene Expression Profile
Study Status: Active/Enrolling
Investigator: Rodriguez, Angel
Study Coordinator: Boone, Toniva
Phone: 7134410686
Summary:This phase II trial is studying how well hormone therapy or chemotherapy before surgery based on gene expression analysis works in treating patients with breast cancer(read more)

NSABP B43
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Sinclair, Toni
Phone: (713) 441-1159
Summary:RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or...(read more)

NSABP B47
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Sinclair, Toni
Phone: (713) 441-1159
Summary:RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination ch...(read more)

NSABP DMP1
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Sinclair, Toni
Phone: (713) 441-1159
Summary:This clinical trial studies factors influencing decision-making about the use of chemoprevention in women at increased risk for breast cancer.(read more)

PROMIS registry of mammaprint in breast cancer
Study Status: Active/Enrolling
Investigator: Rodriguez, Angel
Study Coordinator: Sinclair, Toni
Phone: (713) 441-1159
Summary:This is a prospective registry study that will assess the impact of MammaPrint on chemotherapy + endocrine versus endocrine alone treatment decisions in patients with an Oncotype Intermediate Score.(read more)

S0812 Vitamin D in High Risk Breast Cancer
Study Status: Active/Enrolling
Investigator: Rodriguez, Angel
Study Coordinator: Sinclair, Toni
Phone: (713) 441-1159
Summary:RATIONALE: Cholecalciferol may prevent breast cancer in premenopausal women. PURPOSE: This randomized phase II trial is studying how well cholecalciferol works in preventing breast cancer in premenop...(read more)

S0927 Omega-3 for the Control of AI Induced Musculoskeletal Pain
Study Status: Active/Enrolling
Investigator: Rodriguez, Angel
Study Coordinator: Sinclair, Toni
Phone: (713) 441-1159
Summary:RATIONALE: An omega-3 fatty acid-enriched nutritional supplement may help improve muscle and bone pain and stiffness caused by hormone therapy in patients with breast cancer. PURPOSE: This randomized...(read more)

SWOG 1007
Study Status: Active/Enrolling
Investigator: Rodriguez, Angel
Study Coordinator: Sinclair, Toni
Phone: (713) 441-1159
Summary:RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy, using tamoxifen citrate, may fight breast cancer by blocking the use of estrogen by the tumor cells. Aromatase inhibit...(read more)

TDM4884g TDM1 for HER2 positive Locally Advanced or Metastatic Breast Cancer
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Salazar, Maria
Phone: 713-441-6011
Summary:This is a multicenter, open-label, single-arm, expanded access study designed to provide T-DM1 to patients with HER2-positive locally advanced or metastatic breast cancer and to evaluate the safety an...(read more)

Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects
Study Status: Active/Enrolling
Investigator: Rodriguez, Angel
Study Coordinator: Salazar, Maria
Phone: 713-441-6011
Summary:The purpose of this study is to compare active immunotherapy (OPT-822/OPT-821) with PBS in combination with low dose cyclophosphamide, in post-treated metastatic breast cancer subjects with stable dis...(read more)

Triple Negative RAD 001
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Froehlich, Amber
Phone: 713-441-0685
Summary:RATIONALE: Drugs used in chemotherapy, such as cisplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everol...(read more)
Hematologic Cancers

ENDEAVOR Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Study Status: Active/Enrolling
Investigator: Iyer, Swaminathan
Study Coordinator: Froehlich, Amber
Phone: 713-441-0685
Summary:This Phase 3 study is a multicenter, open-label, randomized trial in patients with multiple myeloma whose disease has relapsed after at least 1 but not more than 3 prior therapeutic regimens. Patients...(read more)
Liver Cancers

IV GC33 in Patients with Advanced or Metastatic HCC
Study Status: Active/Enrolling
Investigator: Monsour, Howard
Study Coordinator: Dorman, Susan
Phone: 713-441-6316
Summary:This randomized, placebo-controlled, multicenter study will evaluate the efficacy and safety of RO5137382 (GC33) in previously treated patients with unresectable advanced or metastatic hepatocellular ...(read more)
Lymphoma

C14012: Alisertib or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Study Status: Active/Enrolling
Investigator: Iyer, Swaminathan
Study Coordinator: Froehlich, Amber
Phone: 713-441-0685
Summary:This is a phase 3, randomized, 2-arm, open-label, international trial evaluating alisertib compared with single-agent treatment, as selected by the investigator from the offered options of pralatrexat...(read more)

MLN8237 in Relapsed or Refractory Aggressive B-Cell Lymphoma - C14011
Study Status: Active/Enrolling
Investigator: Iyer, Swaminathan
Study Coordinator: Woodard, Karen
Phone: 713-441-4332
Summary:This is a single-arm, open-label, multicenter, dose escalation, phase 1-2 study of alisertib (MLN8237) administered in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)/transf...(read more)
Prostate Cancers

LUTS Pilot - VESI-11E02
Study Status: Active/Enrolling
Investigator: Boone, Timothy
Study Coordinator: Whipple, Melissa
Phone: 713-441-3247
Summary:A single center, pilot trial with combination therapy of tamsulosin and solifenacin in 20 men with symptomatic lower urinary tract symptoms (LUTS). Subjects will be evaluated at baseline, 1, 2, and 3 ...(read more)

Vesicare to Improve Urinary Continence after Robotic Assisted Radical Prostatectomy
Study Status: Active/Enrolling
Investigator: Mobley, David
Study Coordinator: Tambourides, Minna
Phone: 832-279-9469
Summary:The purpose of this study is to assess the efficacy and safety of 12 weeks of treatment of VESIcare® versus placebo in subjects who are incontinent after Robotic Assisted Radical Prostatectomy. This ...(read more)
Urinary Tract Cancers

SWOG - S0931 - EVEREST - Renal Cancer
Study Status: Active/Enrolling
Investigator: Lehane, Daniel
Study Coordinator: Bieniemy, Dana
Phone: 713-441-0629
Summary:RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor. PURPOSE: This phase III trial is studying evero...(read more)